Align Technology's stock has surged 21.7% year-to-date in 2026, fueled by a solid fourth-quarter earnings report that revealed an adjusted EPS of $3.29, surpassing Zacks Consensus Estimates by 10.1%. Despite facing challenges such as a 2.2% annualized revenue growth over the past two years and a decreased adjusted operating margin, the company is making strategic advancements, including integrating its iTero scanners with major dental platforms and amending its bylaws to empower shareholders. Recent analyst upgrades, including HSBC's shift from Hold to Buy, reflect growing confidence in Align's market position against competitors like 3M and Henry Schein.